Tests sirolimus in people with dilated heart disease and Kaposi sarcoma virus
Tests sirolimus added to standard care in adults with dilated cardiomyopathy and KSHV infection.
Plain-language title generated from the registry record
Registry title: The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06236022, who can take part
Where in China
- Tongji HospitalWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tongji Hospital
- Trial code
- NCT06236022
- Record updated
- 1 February 2024
- Original description
Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.Read full original descriptionShow less
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.
Inclusion: 18 to 70 years of age; Diagnosed as dilated cardiomyopathy. Specifically, (i) left ventricular ejection fraction <45% (>2 SD) and/or fractional shortening <25% (>2 SD), as ascertained by echocardiography, radionuclide scanning, or cardiac magnetic resonance imaging; (ii) left ventricular end-diastolic diameter >117% of the predicted value corrected for age and body surface area (Henry's formula), which corresponds to 2 SD of the predicted normal limit +5%; and (iii) In the absence of severe coronary artery disease or valvular disease; KSHV DNA seropositivity; Patients are voluntary and signed informed consent.
Exclusion: Participate in any drug clinical trials within 3 months; Allergic to rapamycin or its derivatives；; Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients); Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions; The proportion of neutrophils less than 0.5*10\^9/L or platelet less than 2.5*10\^10/L; Pregnant women or plan to; Patients were not optimally managed.